Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ELOXX PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)

09/13/2021 | 04:09pm EST

Item 7.01. Regulation FD Disclosure.

Eloxx Pharmaceuticals, Inc. (the "Company") will be presenting at H.C. Wainwright's 23rd Annual Global Investment Conference, which is being held from September 13, 2021 through September 15, 2021. A copy of the Company's presentation materials that will be used at the conference is available through the "Events & Presentations" page of the Company's website at https://investors.eloxxpharma.com/events-and-presentations.

The information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses

All news about ELOXX PHARMACEUTICALS, INC.
11/18HC Wainwright Adjusts Eloxx Pharmaceuticals' Price Target to $1 From $2, Keeps Neutral ..
MT
11/17ELOXX PHARMACEUTICALS : Topline ELX-02 Phase 2 Results Call and Webcast
PU
11/17Eloxx Pharmaceuticals' Mid-Stage Cystic Fibrosis Trial Meets Key Secondary Endpoint, Sa..
MT
11/17ELOXX PHARMACEUTICALS : Reports Positive Topline Results from Monotherapy Arms of Phase 2 ..
PU
11/17ELOXX PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial Statements..
AQ
11/17Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2..
AQ
11/17Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2..
CI
11/11HC Wainwright Adjusts Eloxx Pharmaceuticals' Price Target to $2 From $3, Maintains Neut..
MT
11/09Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Pr..
PU
11/09Eloxx Pharmaceuticals, Inc. Appoints Ali Hariri as Chief Medical Officer
CI
More news
Analyst Recommendations on ELOXX PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -64,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,65x
Yield 2021 -
Capitalization 53,7 M 53,7 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 25
Free-Float 90,3%
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 0,62 $
Average target price 3,33 $
Spread / Average Target 435%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial & Accounting Officer
Tomer Kariv Chairman
Vijay Modur Head-Research & Development
Ali Hariri Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-84.35%54
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298